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Abstract
 Objectives—We sought to determine the clinical performance of visual inspection with acetic 
acid (VIA), digital cervicography (DC), Xpert HPV, and OncoE6 for cervical cancer screening in 
an HIV-infected population.
 Methods—HIV-infected women 18 years and older were included in this cross-sectional 
validation study conducted in Lusaka, Zambia. The screening tests were compared to a 
histological gold standard. We calculated sensitivity, specificity, positive and negative predictive 
values, positive and negative likelihood ratios, and odds ratios using cervical intra-epithelial 
neoplasia grade 2 or worse (CIN2+) and grade 3 or worse (CIN3+) thresholds.
 Results—Between January and June 2015, 200 women were enrolled. 15% were screen 
positive by VIA, 20% by DC, 47% by Xpert HPV, and 6% by OncoE6. Using a CIN2+ threshold, 
the sensitivity and specificity of VIA was 48% (95% confidence interval [CI]: 30-67%) and 92% 
(95% CI: 86-95%), respectively. Similarly, the sensitivity and specificity of DC was 59% (95% CI: 
41-76%) and 88% (95% CI: 82-93%). The sensitivity and specificity of Xpert HPV was 88% 
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(95% CI: 71-97%), and 60% (95% CI: 52-68%). Finally, the sensitivity and specificity of OncoE6 
was 31% (95% CI: 16-50%) and 99% (95% CI: 97-100%).
 Conclusions—VIA and DC displayed moderate sensitivity and high specificity. Xpert HPV 
performed equivalently to currently approved HPV DNA tests, with high sensitivity and moderate 
specificity. OncoE6 displayed excellent specificity but low sensitivity. These results confirm an 
important role for VIA, DC, and Xpert HPV in screen-and-treat cervical cancer prevention in low- 
and middle-income countries, such as Zambia.
Keywords
Cervical cancer screening; HIV; clinical performance validation; visual screening; molecular 
screening; low- and middle-income countries
 Introduction
Invasive cervical cancer (ICC) is responsible for much of the cancer-related morbidity and 
mortality among women worldwide, with approximately 85% of the disease burden 
occurring in low- and middle-income countries (LMICs).1,2 HIV-infected women are at 
increased risk of persistent high-risk HPV (hrHPV) infection and cervical cancer precursors, 
as well as a more rapid progression from cancer precursors to ICC.3,4
The vast majority of cervical cancers can be prevented by vaccination against HPV, the 
principal cause of cervical cancer, and by organized, population-based cervical cancer 
screening.5 Comprehensive national programs to promote and provide HPV vaccination and 
cervical cancer screening are urgently needed in sub-Sarahan Africa, Southeast Asia, and 
Latin America. Evaluation of cost-effective and scalable cervical cancer screening and 
treatment modalities is also of central importance in settings of high disease burden, 
including in Zambia where the age-standardized incidence of cervical cancer is above 30 per 
100,0006 and the prevalence of HIV among adults aged 15-49 years is 13%.7
The cost-effectiveness and scalability of visual inspection with acetic acid (VIA) have 
previously been established in various LMIC settings.5,8-10 However, the test's sensitivity is 
moderate.11 Molecular cervical cancer screening – based on the detection of HPV DNA, 
RNA, or oncoproteins – has the potential to overcome some of the shortcomings of VIA. 
While molecular testing was once thought to be cost and resource prohibitive for LMICs, 
newer tests are cheaper, available for use at the point of care, and vastly simplified. These 
advancements enable molecular tests to be more easily integrated into screening algorithms 
in a wide range of settings.
We included 2 such molecular tests in our validation study: Xpert HPV and OncoE6. Xpert 
HPV is a rapid HPV DNA test run on the Cepheid GeneXpert platform, and has a turn-
around-time (TAT) of ∼ 60 minutes. The Arbor Vita OncoE6 test, which detects the 
presence of the HPV E6 oncoprotein, a protein upregulated in ICC and cancer precursors, 
has a TAT of ∼ 90 minutes. The objective of our study was to determine the clinical 
performance (i.e., sensitivity, specificity, positive predictive value, and negative predictive 
value) of VIA, digital cervicography (DC), Xpert HPV, and OncoE6 for cervical cancer 
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screening in HIV-infected women. The screening tests were compared to a histological gold 
standard using both cervical intra-epithelial neoplasia grade 2 or worse (CIN2+) and grade 3 
or worse (CIN3+) thresholds.
 Methods
 Study design and setting
We conducted a cross-sectional clinical performance validation of 4 cervical cancer 
screening tests: 2 visual and 2 molecular. Our study clinic was co-located with a Cervical 
Cancer Prevention Program in Zambia (CCPPZ) clinic on the campus of the University 
Teaching Hospital in Lusaka, Zambia. Since its inception in 2006, CCPPZ has implemented 
cervical cancer screening based on a “see-and-treat” approach, where women undergo visual 
screening, followed by immediate ablation with cryotherapy or cold coagulation 
(thermocoagulation), or referral for biopsy. CCPPZ has screened over 300,000 women 
through see-and-treat services provided within the public clinics and is integrated within the 
PEPFAR-supported HIV care and treatment infrastructure.12,13 Trained nurses apply acetic 
acid to the cervix (VIA), looking with the naked eye for acetowhite changes and vascular 
abnormalities. In our setting, VIA is routinely augmented with DC, which uses digital 
photographs captured with a commercial brand camera for magnification, patient education, 
telemedicine support, and quality assurance.14-16
 Study population and procedures
Women attending the CCPPZ screening clinic were invited to participate in our study. HIV-
infected women 18 years and older were eligible for inclusion. Pregnant women were 
excluded. After written informed consent, demographic and clinical information was 
collected on standardized case report forms. All participants then underwent pelvic 
examination with cervical samples for Xpert HPV (GeneXpert, Cepheid, 2014, Sunnyvale, 
CA, USA) and OncoE6 (Arbor Vita, 2013, Fremont, CA, USA) collected using a cytobroom 
and placed in ThinPrep solution (Hologic, 2005, Marlborough, MA, USA). Thinprep 
collection was followed by VIA and then DC, after which all participants underwent two-
quadrant cervical biopsies to obtain tissue specimens for histology.17 For those with 
acetowhite changes, cervical biopsies were obtained from areas of the transformation zone 
that appeared abnormal (i.e., the worst-appearing lesions). For women with no acetowhite 
changes, biopsies were obtained from 6 and 12 o'clock. Biopsy specimens were placed in 
10% buffered formalin. Finally, blood samples were collected for HIV plasma viral load and 
CD4+ count testing.
VIA and DC results were communicated to participants during the initial study visit. Women 
returned 2-4 weeks after the initial visit to receive their histology results, HIV viral load, and 
CD4+ count, as well as additional treatment recommendations. (The results of the Xpert 
HPV and OncoE6 tests were not communicated to participants, nor were they incorporated 
into recommendations for clinical management, as neither test has been approved for clinical 
use in Zambia.) In accordance with CCPPZ clinical guidelines, those diagnosed with CIN1+ 
were referred to the CCPPZ clinic for further management of CIN, with either ablative or 
excisional treatment, or to the University Teaching Hospital or Cancer Diseases Hospital for 
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further management of ICC. Women with no intra-epithelial lesion or malignancy (NILM) 
seen on histology were counseled to return for routine screening in 3 years. With the 
woman's permission, HIV viral load and CD4+ cell count results were also communicated to 
her HIV treatment clinic.
 Laboratory testing
Cervical Thinprep (Hologic, 2005, Marlborough, MA, USA) samples were transported from 
the study clinic to the Centre for Infectious Disease Research in Zambia (CIDRZ) Central 
Laboratory and stored at room temperature for ∼ 90 days before testing by Xpert HPV and 
OncoE6 in accordance with the manufacturers' instructions. The Xpert HPV test 
(GeneXpert, Cepheid, 2014, Sunnyvale, CA, USA) carries out multiplexed amplification of 
target DNA by real-time PCR of 13 hrHPV types and 1 possible hrHPV type (HPV66) in a 
single cartridge-based analysis. Xpert HPV identifies HPV16 and HPV18/45 in two distinct 
detection channels and reports 11 other HPV types (HPV31/33/35/39/51/52/56/58/59/66/68) 
as a pooled result. A human reference gene (hydroxymethylbilane synthase [HMBS]), which 
confirms sample adequacy, and internal probe checks are integrated within the test cartridge. 
The OncoE6 test (Arbor Vita, 2013, Fremont, CA, USA) is based on the capture and 
detection of E6 proteins from HPV16 and HPV18 using high-affinity monoclonal antibodies 
in a lateral-flow assay. The E6 proteins are detected by an alkaline phosphatase-conjugated 
monoclonal antibody, and a positive result is visualized by the addition of an enzyme 
substrate.
Cervical biopsies stored in formalin were transported to the Cancer Disease Hospital 
Pathology Department, embedded in paraffin, sectioned, stained with hemotoxylin and 
eosin, and read by a certified pathologist to determine the histologic diagnosis. Blood 
samples collected in EDTA tubes were transported to the CIDRZ Central Laboratory on the 
day of collection. Plasma was isolated from the blood samples and analyzed for HIV-1 viral 
load and CD4+ cell counts. Viral load was measured using the Cobas Ampliprep/Taqman 
platform (Roche Molecular Diagnostics, 2007, Pleasanton, CA, USA) and CD4+ cell count 
using an FC500 flow cytometer (Beckman Coulter, 2004, Pasadena, CA, USA) according to 
the manufacturers' recommendations.
 Statistical analysis
Demographic, clinical, and laboratory data were entered into a custom-built database. Data 
were cleaned in MS Excel (Microsoft, 2015, Redmond, WA, USA) and exported to Stata 
version 12.1 (StataCorp, 2012, College Station, TX, USA) for analysis. Our primary 
outcome was clinical performance (sensitivity, specificity, PPV, NPV) of VIA, DC, Xpert 
HPV, and OncoE6 for identification of CIN2+. Our secondary outcomes included clinical 
performance of the tests for CIN3+, as well as likelihood ratios (LRs), odd ratios (ORs), and 
number needed to screen.
Descriptive analysis included generating frequencies, measures of central tendency, and 
measures of variability for demographic and clinical variables. Missingness was also 
assessed for each variable. We then calculated the sensitivity, specificity, PPV, and NPV of 
all 4 screening tests for identification of both CIN2+ and CIN3+. The point estimates of 
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these parameters are reported with corresponding 95% confidence intervals (CIs). For each 
of the screening tests, we also determined the positive and negative LRs and the odds of 
CIN2+ or CIN3+ among women who were screen positive compared to those who were 
screen negative. Once again, point estimates of the LRs and ORs are reported with 
corresponding 95% CIs.
 Ethics statement
Regulatory approval was provided by the University of Zambia's Biomedical Research 
Ethics Committee and the University of North Carolina at Chapel Hill's Institutional Review 
Board. All participants provided written informed consent.
 Role of the funding source
Financial support was provided through the National Cancer Institute Award 
1D43CA153784, the Fogarty International Center Award R25TW009340 to the UNC 
Hopkins Morehouse Tulane Fogarty Global Health Fellows Program, and a Fulbright-
Fogarty Fellowship Award. The funding agencies had no role in the study design, data 
collection, analysis, interpretation of findings, and manuscript writing, or in the decision to 
submit the manuscript for publication.
 Results
 Characteristics of the study participants
Between January and June 2015, 200 eligible HIV-infected women were enrolled. The 
median age of women in the study was 42 years (interquartile range [IQR]: 34-47). Roughly 
half of the participants had completed at least some secondary school education (47%) and 
were married to or cohabiting with their primary partner (47%) (Table 1).
Participants were asked to provide a brief gynecologic and sexual history. The median age of 
sexual debut was 18 years (IQR: 16-20) and the median number of lifetime sexual partners 
was 3 (IQR: 2-5). Although vaginal “cleansing” with herbs, detergents, cloth, and similar 
items is thought to be common in settings like Zambia, only 27 (14%) women reported this 
practice. Encouragingly, 90 (46%) participants reported prior cervical cancer screening by 
VIA, 179 (90%) were receiving antiretroviral therapy (ART), and 153 (77%) had an HIV 
viral load < 20 copies/mL. The median CD4+ cell count was 456 cells/uL (IQR: 328-590). 
Despite the overwhelming majority of women receiving ART and being virologically 
suppressed, however, the burden of cervical disease in this population was high. Six (3%) 
women were diagnosed with ICC. Additionally, 14 (7%) women had CIN3, 12 (6%) had 
CIN2, and 35 (18%) had CIN1.
 Screening test positivity
Twenty-nine (15%) women were screen positive by VIA, 30 (20%) by DC, 94 (47%) by 
Xpert HPV, and 11 (6%) by OncoE6. The Xpert HPV test also provided results for HPV16 
and HPV18/45, for which 29 (15%) and 22 (11%) women were positive, respectively. Using 
OncoE6, 9 (5%) women were HPV16 positive and 3 (2%) HPV18 positive. There were no 
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statistically significant differences in the proportion of screen positive women by ART status 
(Table 2).
 Clinical performance using a CIN2+ threshold
Using a CIN2+ threshold, the sensitivity and specificity of VIA was 48% (95% CI: 30-67%) 
and 92% (95% CI: 86-95%), respectively. Similarly, the sensitivity and specificity of DC 
was 59% (95% CI: 41-76%) and 88% (95% CI: 82-93%). The sensitivity and specificity of 
Xpert HPV was 88% (95% CI: 71-97%) and 60% (95% CI: 52-68%). The sensitivity and 
specificity of OncoE6 was 31% (95% CI: 16-50%) and 99% (95% CI: 97-100%) (Table 3).
Compared to women who were screen negative, the odds of CIN2+ was 10 times higher 
among women who were VIA positive (95% CI: 4-25), and 11 times higher among those 
DC positive (95% CI: 4-25) and Xpert HPV positive (95% CI: 4-30). Additionally, we 
determined that to detect 1 case of CIN2+, 13 women would need to be screened by VIA, 11 
women by DC, 7 by Xpert HPV, and 20 by OncoE6.
 Clinical performance using a CIN3+ threshold
Using a CIN3+ threshold, the sensitivity and specificity of VIA was 63% (95% CI: 38-84%) 
and 91% (95% CI: 85-94%), respectively. Similarly, the sensitivity and specificity of DC 
was 75% (95% CI: 51-91%) and 87% (95% CI: 81-91%). The sensitivity and specificity of 
Xpert HPV was 90% (95% CI: 68-99%) and 57% (95% CI: 48-65%). Finally, the sensitivity 
and specificity of OncoE6 was 40% (95% CI: 19-64%) and 98% (95% CI: 95-100%).
The results of the likelihood ratio analysis for CIN3+ were similar to those obtained using a 
CIN2+ threshold. However, the confidence intervals were wider because we had relatively 
few cases of CIN3+ (Table 4). The calculation of the number needed to screen also showed a 
similar trend, such that to detect 1 case of CIN3+ 17 women would need to be screened by 
VIA, 13 women by DC, 11 by Xpert HPV, and 25 by OncoE6.
 Discussion
Our study confirms a substantial risk of CIN2+ among HIV-infected Zambian women 
receiving combination ART (cART), nearly half of whom had previously been screened for 
cervical cancer. Specifically, 3% of women were diagnosed with ICC and 13% with high-
grade CIN. It should be noted that the burden of cervical disease in our study was somewhat 
lower than in previously published Zambian studies, which have reported that ∼30-50% of 
HIV-infected women are VIA/DC positive,18,19 20% have CIN2+,19 and 53% are hrHPV 
positive.20 These studies were conducted before cART was widely available in Zambia and 
before the introduction of the so-called Option B+ strategy (through which the 
overwhelming majority of HIV-infected women of reproductive age have obtained access to 
cART regardless of their CD4+ cell count), possibly accounting for the observed differences.
The visual screening tests evaluated (VIA and DC) both displayed moderate sensitivity and 
high specificity for CIN2+ (sensitivity: 48% and 59%, respectively; specificity: 92% and 
88%), which is broadly consistent with previously published validation data.11,15,21 Not 
surprisingly, Xpert HPV, an HPV DNA PCR assay, demonstrated high sensitivity and 
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moderate specificity for CIN2+ (88% and 60%, respectively). Previous validation studies of 
the Xpert HPV in the U.S. have yielded similar results, with the initial evaluation (n=141) 
demonstrating that Xpert HPV was equally sensitive for high-grade squamous intra-
epithelial lesions (HSIL) as Cobas HPV (90.8% vs. 90.8%) and more sensitive than Digene 
HC2 (90.8% vs. 81.6%, p=0.004). Xpert HPV was also more specific than Cobas HPV 
(42.6% vs. 39.6%, p=0.02) but less specific than Digene HC2 (42.6% vs. 47.7%, p<0.001). 
Our study adds evidence that Xpert HPV performs well in HIV-infected women and, as 
expected, appears to have higher PPV for CIN2+ than in HIV-uninfected women.22 Again, 
not surprisingly, OncoE6, a lateral flow oncoprotein assay, demonstrated high specificity but 
low sensitivity (99% and 31%, respectively) for CIN2+. This finding was similar to 
previously published OncoE6 validation data.23
All of the tests we selected for our validation study can be performed at (or near) the point-
of-care, a characteristic of great importance when considering which testing modalities to 
scale in screen-and-treat cervical cancer prevention programs. Same-day screening and 
treatment services are highly efficient,24 and offer women and providers several advantages. 
First, they reduce attrition from care, a near-ubiquitous problem in both non-communicable 
disease care and HIV treatment programs across sub-Saharan Africa.25,26 Second, same-day 
services have the potential to decrease health care costs, as well as the financial burden that 
women and their families face when multiple return visits are required to obtain test results, 
referral, and treatment.
Although well established, it bears repeating that limited access to cervical cancer screening, 
prevention, and treatment services is among the most important reasons for the disparities in 
cervical cancer incidence and mortality observed globally between high and low- and 
middle-income countries, between urban and rural women, and between rich and poor 
women.27 Screen-and-treat programs can help to address these disparities. We have 
previously shown that in the CCPPZ VIA/DC see-and-treat program, 1 cancer death is 
prevented for every 46 HIV-infected women screened (range: 28–68).28 A landmark 
randomized trial conducted by Denny and colleagues in South Africa also showed that for 
every 100 women screened, a VIA see-and-treat strategy can prevent 7 cases of CIN2+ 
among HIV-infected women and 1 case among HIV-uninfected women. Among 100 women 
screened using an HPV test-and-treat strategy, 12 cases of CIN2+ would be prevented 
among HIV-infected women and 3 among HIV-uninfected women.29 Encouragingly, the 
cost-effectiveness of both screen-and-treat approaches has also been confirmed.5,8,24 With 
the efficacy and cost-effectiveness of screen-and-treat cervical cancer prevention proven, 
what remains to be seen is how rapidly and how fully global guidance30 can be implemented 
and scaled to reduce the burden of this preventable cancer, including among HIV-infected 
individuals who are at the highest risk of cervical disease.
We acknowledge several limitations of our work. As noted above, the burden of cervical 
disease in our study population was somewhat lower than anticipated, affecting measures of 
variability, such as 95% confidence intervals. We were also unable to evaluate the other 
available near-patient HPV DNA test, careHPV, or other FDA-approved HPV tests (e.g., 
Digene HC2 and Roche Cobas HPV) due to limited commercial availability of these tests in 
Zambia. Despite these limitations, we anticipate that our work will help to expand the 
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nascent literature on point-of-care molecular diagnostics for cervical cancer screening and to 
create a foundation for future clinical and implementation science research exploring 
optimal strategies for HPV-based screening in LMICs.
 Conclusions
Among HIV-infected women, VIA and DC displayed moderate sensitivity and high 
specificity, Xpert HPV high sensitivity and moderate specificity, and OncoE6 excellent 
specificity but low sensitivity. Based on these results, we recommend that future evaluations 
of screen-and-treat cervical cancer prevention modalities include HPV DNA testing with the 
GeneXpert platform, as well as with VIA/DC to determine the comparative effectiveness of 
these strategies for reducing CIN2+. Due to its poor sensitivity, OncoE6 is not recommended 
for primary screening, but may be investigated as a triage test. Importantly, we also show 
that the burden of hrHPV and CIN2+ among HIV-infected Zambian women remains 
substantial despite rapidly increasing access to cART and measurable improvements in 
immune function.
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 List of all abbreviations and acronyms
ART Antiretroviral therapy
cART Combination antiretroviral therapy
CCPPZ Cervical cancer prevention program in Zambia
CI Confidence interval
CIDRZ Centre for Infectious Disease Research in Zambia
CIN Cervical intra-epithelial neoplasia
DC Digital cervicography
DNA Deoxyribonucleic acid
FDA Food and Drug Administration
HC2 Hybrid Capture 2
HIV Human immunodeficiency virus
HMBS Hydroxymethylbilane synthase
HPV Human papillomavirus
hrHPV High-risk human papillomavirus
ICC Invasive cervical cancer
IQR Interquartile range
LMICs Low- and middle-income counties
LR Likelihood ratio
mL Milliliter
NILM No intra-epithelial lesion or malignancy
NPV Negative predictive value
OR Odds ratio
PEPFAR President's Emergency Plan for AIDS Relief
PPV Positive predictive value
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RNA Ribonucleic acid
SIL Squamous intra-epithelial lesion
uL Microliter
VIA Visual inspection with acetic acid
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Table 1
Descriptive characteristics of the study participants
Total (N, %)
Age (n=200), median years (IQR) 42 (34-47)
Education (n=200)
 No education 1 (1%)
 Primary education 48 (24%)
 Secondary education 93 (47%)
 Tertiary education 58 (29%)
Marital status (n=200)
 Never married 21 (11%)
 Married/cohabiting 93 (47%)
 Divorced/separated 30 (15%)
 Widowed 56 (28%)
Tobacco use (n=199)
 Yes 10 (5%)
Age at sexual debut (n=186), median (IQR) 18 (16-20)
Lifetime sexual partners (n=188), median (IQR) 3 (2-5)
Number of pregnancies (n=197), median (IQR) 3 (2-5)
Vaginal cleansing (n=196)
 Yes 27 (14%)
Prior cervical screening (n=194)
 Yes 90 (46%)
On antiretroviral therapy (n=199)
 Yes 179 (90%)
CD4+ cell count (n=), median cells/uL (IQR) 456 (328-590)
HIV plasma viral load (n=200)
 <20 copies/mL 153 (77%)
IQR: interquartile range
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Table 2
Screening test positivity for VIA, DC, Xpert HPV, and OncoE6 by antiretroviral status
Total On antiretroviral therapy Not on antiretroviral therapy
VIA (n=199)
 Positive 29 (15%) 24 (14%) 5 (25%)
DC (n=200)
 Positive 39 (20%) 33 (18%) 6 (30%)
Xpert HPV (n=199)
 Any hrHPV positive 94 (47%) 82 (46%) 12 (60%)
 HPV16 positive 29 (15%) 26 (15%) 3 (15%)
 HPV18/45 positive 22 (11%) 20 (11%) 2 (10%)
 HPV31/33/35/52/58 positive 64 (32%) 54 (30%) 10 (50%)
 HPV51/59 positive 14 (7%) 13 (7%) 1 (5%)
 HPV39/68/56/66 positive 18 (9%) 15 (8%) 3 (15%)
OncoE6 (n=200)
 Any hrHPV positive 11 (6%) 11 (6%) 0
 HPV16 positive 9 (5%) 9 (5%) 0
 HPV18 positive 3 (2%) 3 (2%) 0
VIA: visual inspection with acetic acid; DC: digital cervicography;
*p<0.05;
**p<0.01;
***p<0.001
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Table 3
Clinical performance of the cervical cancer screening tests using a CIN2+ threshold
VIA DC Xpert HPV OncoE6
True positive 15 19 28 10
False positive 14 20 66 1
True negative 153 147 100 166
False negative 16 13 4 22
Sensitivity (95% CI) 48% (30-67%) 59% (41-76%) 88% (71-97%) 31% (16-50%)
Specificity (95% CI) 92% (86-95%) 88% (82-93%) 60% (52-68%) 99% (97-100%)
PPV (95% CI) 52% (33-71%) 49% (32-65%) 30% (21-40%) 91% (59-100%)
NPV (95% CI) 91% (85-95%) 92% (87-96%) 96% (90-99%) 88% (83-93%)
PLR (95% CI) 10 (4-25) 5 (3-8) 2 (2-3) 52 (7-394)
NLR (95% CI) 0.6 (0.4-0.8) 0.5 (0.3-0.7) 0.2 (0.1-0.5) 0.7 (0.5-0.9)
OR (95% CI) 10 (4-25) 11 (4-25) 11 (4-30) 76 (12-.)
VIA: visual inspection with acetic acid; DC: digital cervicography; 95% CI: 95% confidence interval; PPV: positive predictive value; NPV: 
negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio; OR: odds ratio
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Table 4
Clinical performance of the cervical cancer screening tests using a CIN3+ threshold
VIA DC Xpert HPV OncoE6
True positive 12 15 18 8
False positive 17 24 76 3
True negative 162 155 102 176
False negative 7 5 2 12
Sensitivity (95% CI) 63% (38-84%) 75% (51-91%) 90% (68-99%) 40% (19-64%)
Specificity (95% CI) 91% (85-94%) 87% (81-91%) 57% (48-65%) 98% (95-100%)
PPV (95% CI) 41% (24-61%) 39% (23-55%) 19% (12-29%) 73% (39-94%)
NPV (95% CI) 96% (92-98%) 97% (93-99%) 98% (93-100%) 94% (89-97%)
PLR (95% CI) 7 (4-12) 6 (4-9) 2 (2-3) 24 (7-83)
NLR (95% CI) 0.4 (0.2-0.7) 0.3 (0.1-0.6) 0.2 (0.1-0.6) 0.6 (0.4-0.9)
OR (95% CI) 16 (6-46) 19 (7-56) 12 (3-.) 39 (10-154)
VIA: visual inspection with acetic acid; DC: digital cervicography; 95% CI: 95% confidence interval; PPV: positive predictive value; NPV: 
negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio; OR: odds ratio
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